Business Of Biotech
by Ben Comer
Is this your podcast?Ben Comer is an independent podcast creator known for his expertise in the biopharma industry, particularly in guiding emerging biotech firms through complex challenges. His insights stem from a deep understanding of the intersection betwee…
Insights from recent episode analysis
Audience Interest
- biopharma industry insights
- organizational challenges
Podcast Focus
- biopharma leadership
- best practices sharing
Publishing Consistency
- 302 episodes total
- active for six years
Platform Reach
- available on major platforms
- no specific platforms listed
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 21 chart positions in 21 markets.
By chart position
- 🇺🇸US · Management#6230K to 100K
- 🇬🇧GB · Management#1875K to 30K
- 🇰🇷KR · Management#8100K to 300K
- 🇲🇽MX · Management#4030K to 100K
- 🇯🇵JP · Management#6310K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
108K to 366K🎙 ~2x weekly·302 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
217K to 731K🇰🇷41%🇺🇸14%🇲🇽14%+18 more - Active Followers
Loyal subscribers who consistently listen
65K to 219K4.1K real followers tracked across platforms
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 22 epsHosts
Recent guests
Recent episodes
Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.
Jul 20, 2026
56m 27s
BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin
Jul 13, 2026
48m 57s
BoB@BIO: Biotech Investing And Deals With Sofinnova's Maha Radhakrishnan, M.D.
Jul 6, 2026
39m 07s
Targeting Tau in Alzheimer's Disease With Voyager Therapeutics' Al Sandrock, M.D., Ph.D.
Jun 29, 2026
48m 34s
Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho
Jun 22, 2026
55m 13s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/20/26 | late-stage developmentcommercial planning+3 | Matt Winton, Ph.D. | neflamapimodCervoMed | — | CervoMedneflamapimod+5 | — | 56m 27s | ||
| 7/13/26 | public distrustbiotech leadership+3 | Dr. Jeremy Levin | Ovid Therapeutics | — | biotechpublic distrust+3 | — | 48m 57s | ||
| 7/6/26 | biotech investingprivate equity+4 | Maha Radhakrishnan, M.D. | SofinnovaBIO Convention+5 | San Diego | biotechinvesting+5 | — | 39m 07s | ||
| 6/29/26 | Alzheimer's Diseasetau protein+4 | Al Sandrock, M.D., Ph.D. | Voyager TherapeuticsBusiness of Biotech | — | Alzheimer'stau+5 | — | 48m 34s | ||
| 6/22/26 | cell therapycancer treatment+3 | William Ho | gamma delta T cellsIN8bio | glioblastoma | cell therapygamma delta T cells+5 | — | 55m 13s | ||
| 6/15/26 | drug launchbiotech+3 | William Soliman | Accreditation Council for Medical AffairsWhite Manna Capital Partners | — | biotechdrug launch+3 | — | 55m 18s | ||
| 6/8/26 | life sciences industryAI manufacturing+3 | — | Bioprocess OnlineLife Science Connect+1 | 2026 | life sciencesAI+3 | — | 1h 24m 17s | ||
| 6/1/26 | CNS Drug DevelopmentNeuroscience+3 | Jeff Jonas, M.D. | Tortugas Neuroscience | — | CNSDrug Development+5 | — | 49m 52s | ||
| 5/25/26 | rare diseasedrug commercialization+3 | Neil McFarlane | Niemann-Pick disease type CZevra Therapeutics | — | rare diseasedrug commercialization+5 | — | 55m 23s | ||
| 5/18/26 | manufacturingpersonalized therapies+5 | Marinna Madrid, Ph.D. | Cellino | — | personalized medicinecell therapy+5 | — | 50m 55s | ||
| 5/11/26 | antibody discoverysingle-cell biology+3 | Wyatt McDonnell, Ph.D. | InfinimmuneMerck | — | antibody drugsInfinimmune+3 | — | 54m 12s | ||
| 5/4/26 | antisense oligonucleotidesRNA-targeting medicines+3 | Brett Monia, Ph.D. | Ionis Pharmaceuticals | — | ASO therapiesIonis Pharmaceuticals+5 | — | 55m 56s | ||
| 4/27/26 | CEO strategyneuroreparative peptide+3 | Adam Rogers, M.D.Rich Macary | NVG-291NervGen+2 | — | NervGenNVG-291+5 | — | 47m 37s | ||
| 4/20/26 | FDA decision-makingclinical trial strategy+3 | Allan Shaw | FDA | — | FDAbiotech+5 | — | 46m 53s | ||
| 4/13/26 | biosimilarsFDA regulations+3 | Sarfaraz Niazi, Ph.D. | FDABiologics Price Competition and Innovations Act | — | biosimilarsFDA+5 | — | 58m 33s | ||
| 4/6/26 | radiotherapeuticsneuroendocrine tumors+3 | Thijs Spoor | Pb 212radiopharmaceuticals+1 | — | radiotherapeuticsneuroendocrine tumors+3 | — | 40m 26s | ||
| 3/30/26 | oncologyinvestment+3 | Dan McHugh | Yosemite | — | oncologyinvestment+5 | — | 55m 41s | ||
| 3/23/26 | CAR T therapybiotech commercialization+3 | Alan Bash | CarvyktiLegend Biotech+3 | — | CAR T therapyCarvykti+5 | — | 50m 57s | ||
| 3/16/26 | radiotherapeuticsCNS cancers+4 | Marc Hedrick, M.D. | ReyobiqPlus Therapeutics+2 | — | radiotherapeuticsCNS cancers+5 | — | 54m 00s | ||
| 3/9/26 | cancer drug developmentcapital efficiency+3 | Rahul Aras, Ph.D. | Iterion Therapeutics | — | cancerdrug development+4 | — | 48m 30s | ||
| 3/2/26 | biologicsoral drugs+3 | Thomas von Erlach, Ph.D.Thomas von Erlach | VivtexNovo Nordisk | MIT | biologicsoral availability+7 | — | 53m 57s | ||
| 2/23/26 | leadershipculture+3 | Monika Sumra, Ph.D. | Bunka, Inc. | — | leadershipculture+5 | — | 58m 19s |
Showing 22 of 22
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Similar Audience Demographics
Podcasts that attract a similar listener profile
Distribution & Reach
About the show, platforms, and key insights.
Distribution & Reach
About the show, platforms, and key insights.
Ben Comer is an independent podcast creator known for his expertise in the biopharma industry, particularly in guiding emerging biotech firms through complex challenges. His insights stem from a deep understanding of the intersection between business and science, making him a valuable voice in the field. The Business of Biotech podcast distinguishes itself by focusing on the specific hurdles faced by leaders in the emerging biopharma sector. Covering a range of topics from finance and HR to regulatory compliance, the show features expert commentary and best practices from industry founders and luminaries. Each episode is designed to provide actionable insights, helping listeners navigate their journey from concept to clinical success. The podcast attracts a diverse audience of professionals in the biotech and biopharma sectors, including entrepreneurs, investors, and executives seeking to enhance their strategic knowledge. Listeners gain significant value from the practical advice and firsthand experiences shared by guests, empowering them to make informed decisions and drive their companies forward.
By the numbers
- Total followers: 4.1K
- Total plays: 237K
- Total reviews: 84
Platforms
TuneIn
- Followers: 57
Castbox
- Followers: 290
- Plays: 9.3K
YouTube
- Subscribers: 3.6K
- Views: 227K
- Videos: 1.9K
Podcast App
- Followers: 85
- Reviews: 84
Podcast Republic
- Followers: 30
Audience
professionals, adults
Key insights
What the show covers
- biopharma leadership
- best practices sharing
- clinical success navigation
- guest commentary
Audience interests
- biopharma industry insights
- organizational challenges
- funding and finance
- regulatory issues
Platform reach
- available on major platforms
- no specific platforms listed
- growing newsletter audience
- produced by Life Science Connect
Publishing consistency
- 302 episodes total
- active for six years
- weekly episode cadence
- consistent content delivery
Chart history for Business Of Biotech
Peaked at #8 in South Korea, top 10 in 1 of 22 tracked markets, currently #8 in South Korea.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| South Korea | — | #8 | #8 | — |
| GR | — | #23 | #23 | — |
| KE | — | #39 | #39 | — |
| Mexico | — | #40 | #40 | — |
| CZ | — | #47 | #47 | — |
| United States | — | #62 | #62 | — |
| Japan | — | #63 | #63 | — |
| IL | — | #75 | #75 | — |
| HK | — | #104 | #104 | — |
| TR | — | #117 | #117 | — |
| CO | — | #127 | #127 | — |
| TW | — | #135 | #135 | — |
| Denmark | — | #140 | #140 | — |
| Spain | — | #142 | #142 | — |
| Netherlands | — | #145 | #145 | — |
| South Korea | — | #160 | #160 | — |
| Norway | — | #162 | #162 | — |
| Brazil | — | #170 | #170 | — |
| HU | — | #172 | #172 | — |
| United Kingdom | — | #187 | #187 | — |
Chart Positions
22 placements across 21 markets.
Chart Positions
22 placements across 21 markets.